Avillion Asthma Trial Demonstrates Significant Benefits for Asthma Patients
London, UK, 9 September 2021 – Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced positive high-level results from the MANDALA and DENALI Phase III trials of a new, fixed-dose combination inhaler for those who suffer from asthma. JoinAStudy.ca Investigators Dr. Syed Anees, Dr. Peter Dzongowski, Dr. Anil Gupta, Dr. Sam Henein and Dr. Sean
